For the millions of people in the UK living with conditions like Hashimotos thyroiditis or hypothyroidism, these medicationsoriginally developed for type 2 diabetescan be a significant tool for managing metabolic health
doi: 10.1007/s12325-017-0595-7 Summary Keywords dipeptidyl peptidase-IV inhibitor, efficacy, glucagon-like peptide-1, linagliptin, prediabetes, type 2 diabetes Citation Chong SC, Sukor N, Robert SA, Ng KF and Kamaruddin NA (2022) Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
Derivatives : Structural variations of the main compound are filed as part of the main patents for the broadest protection
Am J Phys Med Rehabil
Harada K, Takashima M, Kitaguchi T, Tsuboi T
Table 2 Parameters of the female offspring at different ages